NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1155.90 7.90 (0.69%)

1.4M NSE+BSE Volume

NSE 09 May, 2025 3:31 PM (IST)

96,454.7

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

10 May 2024, 12:00AM

1155.90

0.69%

Lack of near term key product launches to affect growth momentum

Sell: Dr. Reddy's Laboratories Ltd.

Recommendation Target

KRChoksey

The company met our estimates across lines for FY24; outperformed on sales/Gross Profits (+6.5%/+7.9%) basis but underperformed on EBITDA/adj. PAT (-2.2%/-5.1%) basis in Q4FY24
? The company is in an extensive R&D and marketing and promotions mode in order to bring out more NCEs, Consumer Health and biosimilar products to mitigate impact of its key product in the US like gRevlimid going off patent by the beginning of Q4FY26

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1158.4

Dr. Reddy's Laboratories Ltd.

09 May 2024

1155.90

0.69%

Dr Reddy's Labs (HOLD): Driven by North America; India continues to underperform

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

DRRD reported largely in-line revenue/EBITDA, but higher tax aided in PAT beat

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1158.4

Dr. Reddy's Laboratories Ltd.

08 May 2024

1155.90

0.69%

DR REDDY'S LABS

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1158.4

Dr. Reddy's Laboratories Ltd.

08 May 2024

1155.90

0.69%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Axis Direct

We have HOLD on the stock.

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

08 May 2024

1155.90

0.69%

Dr. Reddy Laboratories

Results Update: Dr. Reddy's Laboratories Ltd.

SMC online

Dr. Reddy's Laboratories Ltd. is trading above its 50 day SMA of 1151.4

Dr. Reddy's Laboratories Ltd.

07 May 2024

1155.90

0.69%

US/India drive earnings growth

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr. Reddy’s Lab (DRRD) delivered 4QFY24 revenue in line with our estimate.
However, EBITDA was lower than expected due to higher SGA expenses and
R&D spending. In addition to US generics/branded generics segments, DRRD is
enhancing its offering through JVs/partnerships/acquisitions in nutraceuticals,
vaccine, women’s health and dietary supplement space.

Dr. Reddy's Laboratories Ltd. is trading above its 50 day SMA of 1151.4

Dr. Reddy's Laboratories Ltd.

01 Apr 2024

1155.90

0.69%

Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Sharekhan

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1158.4

Dr. Reddy's Laboratories Ltd.

01 Feb 2024

1155.90

0.69%

First Light | Maruti Suzuki, Dr Reddy's Labs, Voltas, Dixon Technologies, Kajaria Ceramics, Blue Star, KEC International, Aditya Birla Sun Life AMC, Metals & Mining

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

MSIL: Healthy all-round performance raise to BUY. DRRD: Buoyant US sales drive performance. VOLT: UCP improving, Qatar business a dampener. DIXON: Mobile business dials up growth; maintain BUY. KJC: Soft demand, intense competition mar quarter. BLSTR: Purple patch continues; maintain BUY. KECI: Pipeline robust, margin improvement delayed. ABSLAMC: Double-digit growth but market share bleed continues. Metals & Mining: Jindal Stainless: Management meet takeaways

Dr. Reddy's Laborato.. has an average target of 1347.12 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

01 Feb 2024

1155.90

0.69%

Lack of near term key product launches to affect growth momentum

Hold: Dr. Reddy's Laboratories Ltd.

Target

KRChoksey

In Q3FY24, Dr. Reddy’s posted a 6.6% Y-o-Y (+4.8% Q-o-Q) rise in revenue to Rs. 72,368 Mn (vs. our estimate of Rs. 71,872 Mn). The growth was driven by US sales (53.1% of revenue) growing at 9.6% Y-o-Y (+5.7% Q-o-Q) to Rs. 33,492 Mn (vs. our estimate of Rs. 32,707 Mn), 4.7% Y-o-Y (-0.5% Q-o-Q) growth in India revenue (18.7% of revenue) to Rs. 11,800 Mn (vs. our estimate of Rs. 11,950 Mn), 15.5% Y-o-Y (-6.0% Q-o-Q) rise in Europe revenue (7.9% of revenue) to Rs. 4,970 Mn (vs. our estimate of Rs. 5,207 Mn) while PSAI revenue (10.9% of revenue) increased 1.0% Y-o-Y (+11.4% Q-o-Q) to Rs. 7,839 Mn (vs. our estimate of Rs. 7,913 Mn); partially offset by Emerging Market revenue declining at 2.0% Y-o-Y (+5.5% Q-o-Q) to Rs. 12,833 Mn (vs. our estimate of Rs. 13,359
Mn).